Skip to content

Secondary Analysis of Gut Hormones and Inflammatory Cytokines in Fasting Subjects

Effects of Four-day Fast on Gut-derived Hormones and Inflammatory Markers in Healthy, Normal-weight Women.

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01257841
Enrollment
20
Registered
2010-12-10
Start date
2002-11-30
Completion date
2003-12-31
Last updated
2010-12-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Healthy

Keywords

Fasting, Gut hormones, Inflammatory Cytokines

Brief summary

The original study executed between 2002-2004 was an interventional trial in which 20, healthy, normal-weight female subjects were randomized to a four-day fast plus daily subcutaneous injections of leptin or a four day fast plus daily subcutaneous injections of a placebo. The primary endpoints were gonadotropin pulsatility, TSH secretion and thyroid function, and cortisol secretion. The current study is a secondary analysis focussed on the placebo group which underwent a four-day fast. The study is looking at the effects of fasting on gut-derived hormones and inflammatory markers in healthy, normal-weight women. The hypothesis for this secondary analysis was that four days of fasting would augment levels of orexigenic gut-derived hormones and suppress levels of anorexigenic gut-derived horomones, while suppressing secretion of inflammatory cytokines.

Interventions

DRUGLeptin administration

Leptin 0.05 mg/kg sc daily in divided doses (0800, 1400, 2000, and 0200h) for four days.

BEHAVIORALFasting

Complete fasting, save for water and multivitamin, for four days.

Sponsors

Massachusetts Institute of Technology
CollaboratorOTHER
Massachusetts General Hospital
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Masking
DOUBLE (Subject, Investigator)

Eligibility

Sex/Gender
FEMALE
Age
18 Years to 35 Years
Healthy volunteers
Yes

Inclusion criteria

* female age 18-35 * BMI 20-26.0 * eumenorrheic with normal FSH, TSH, Prolactin * Hgb \> 12 g/dL, normal creatinine * normal puberty and development * negative pregnancy test. In addition, subjects agreed not to be sexually active during the course of the inpatient study and to use contraception for a period of 48 hours after discharge from the hospital.

Exclusion criteria

* medical or endocrine problems known to affect thyroid, reproductive, GH or cortisol function * medications known to affect neuroendocrine function * prior history of eating disorder or significant menstrual irregularities * subjects who have a known hypersensitivity to E. Coli derived protein. * subjects with a history of seizure disorder, significant cardiac disease, medication for cardiac disease, or kidney disease * history of anaphylaxis or anaphylactoid like reactions.

Design outcomes

Primary

MeasureTime frameDescription
Hormone levels change from baseline.Change from baseline after 4 days of intervention.Original study looking at gonadotropin pulsitility, TSH secretion and thyroid function, and cortisol secretion. Present study looking at gut-hormone secretion.

Secondary

MeasureTime frame
Levels of inflammatory cytokines change from baseline.Change from baseline after 4 days of intervention.

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026